Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Brainstorm Cell Therapeutics Inc./ S-8

SEC Filing · S-8

Brainstorm Cell Therapeutics Inc.

BCLIOTCEQUITYCurrent

SEC Filing

Filed May 21, 2026Accepted May 20, 2026, 5:34 PM EDTCIK 1137883Accession 0001104659-26-064632
View company →Permanent SEC source ↗
Share

Company context

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company’s proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.

Current securities

BCLIOTC · EQUITY · Current

Recent company filings

  1. 10-Q filingAug 14, 2026
  2. Results of Operations and Financial ConditionAug 14, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureJul 30, 2026
  4. EFFECT filingJun 2, 2026
  5. 4 filingMay 29, 2026

As-filed source

Primary evidence
As filedOpen full document ↗